Juby A. A. Jacob-Nara, MD, MPH, DHSc

Vice President, Global Medical Affairs Respiratory, Allergy, & Gastroenterology
Sanofi

Abstracts(s):

• PC3007: Dupilumab Efficacy in Children with Moderate-to-severe Type 2 Asthma Analyzed by High- or Medium-dose of Inhaled Corticosteroids at Baseline: LIBERTY ASTHMA VOYAGE Study
  Monday, October 10, 2022

  1:30 PM – 2:30 PM US PDT

• PC3021: The Effect of Allergen Sensitization Status on Dupilumab Efficacy in VOYAGE Pediatric Patients with Uncontrolled, Moderate-to-severe Type 2 Inflammatory Asthma
  Monday, October 10, 2022

  1:30 PM – 2:30 PM US PDT